Core Viewpoint - The Hong Kong stock market saw a rise in several innovative drug concept stocks during the morning session, indicating positive investor sentiment in the biotech sector [1] Group 1: Stock Performance - WuXi AppTec (02126.HK) increased by 8.77%, reaching HKD 3.35 [1] - Kintor Pharmaceutical (02171.HK) rose by 3.8%, trading at HKD 18.87 [1] - Beihai Kangcheng (01228.HK) saw a gain of 3.38%, priced at HKD 2.45 [1] - Junshi Biosciences (01877.HK) climbed by 2.29%, with a share price of HKD 24.1 [1]

Core Viewpoint - The article highlights a significant rise in the stock prices of several innovative pharmaceutical companies following the announcement of the 2025 National Medical Insurance drug list, which includes a substantial number of new innovative drugs [1] Group 1: Stock Performance - WuXi AppTec (02126) saw an increase of 8.77%, trading at HKD 3.35 [1] - Kintor Pharmaceutical (02171) rose by 3.8%, reaching HKD 18.87 [1] - Beihai Kangcheng (01228) increased by 3.38%, priced at HKD 2.45 [1] - Junshi Biosciences (01877) gained 2.29%, with a share price of HKD 24.1 [1] Group 2: Drug List Adjustments - The 2025 National Medical Insurance drug list is the 8th adjustment since the establishment of the National Healthcare Security Administration [1] - A total of 114 new drugs were added to the list, including 50 Class 1 innovative drugs [1] Group 3: Notable Drug Inclusions - Fosun Pharma's (600196) Luwomei Tablets and Beihai Kangcheng's injectable Vilazodone Beta were included in the commercial insurance innovative drug list [1] - The highly anticipated CAR-T cell therapies from various companies, including Fosun Kairui's Acalabrutinib Injection and WuXi AppTec's Regorafenib Injection, were also included in the first batch of commercial insurance innovative drug list [1]

智通财经APP获悉，部分创新药概念股早盘走高，截至发稿，药明巨诺-B(02126)涨8.77%，报3.35港 元；科济药业-B(02171)涨3.8%，报18.87港元；北海康成-B(01228)涨3.38%，报2.45港元；君实生物 (01877)涨2.29%，报24.1港元。 值得注意的是，备受瞩目的百万CAR-T细胞疗法——复星凯瑞的阿基仑赛注射液、药明巨诺的瑞基奥仑 赛注射液、合源生物的纳基奥仑赛注射液、驯鹿生物的伊基奥仑赛注射液、恺兴生命科技的泽沃基奥仑 赛注射液均被纳入首批商保创新药目录。 消息面上，2025年国家基本医疗保险、生育保险和工伤保险药品目录是国家医保局成立以来的第8次调 整。本次目录调整新增114种药品，其中50种为1类创新药。据智通财经报道，复星医药的芦沃美替尼片 进入2025年医保目录，北海康成的注射用维拉苷酶β进入商保创新药目录。 ...

Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have issued a new drug catalog for basic medical insurance, maternity insurance, and work injury insurance, which will take effect on January 1, 2026. This marks the 8th adjustment of the medical insurance drug catalog since the establishment of the National Healthcare Security Administration [1] - The recent adjustment adds 114 new drugs, including 50 first-class innovative drugs. Notably, several rare disease medications have been included in the 2025 medical insurance catalog and the commercial health insurance innovative drug catalog [1] - Specific drugs such as Fosun Pharma's Luvofemin and Beihai Kangcheng's Vilazodone have been included in the 2025 medical insurance catalog and the commercial health insurance innovative drug catalog, respectively. Additionally, five CAR-T therapies have been added to the commercial health insurance innovative drug catalog [1] Group 2 - John Yang, the Asia-Pacific healthcare research director at Citibank, stated that biotechnology, particularly innovative drugs, will be a top priority for China in the coming years. He emphasized the need for China to upgrade production lines and capabilities, as well as expand clinical management capabilities to develop the entire ecosystem [1] - Morgan Stanley's healthcare research head in China, Yang Huang, echoed similar sentiments, noting that biomanufacturing has been identified by the government as a key economic growth driver during the 14th Five-Year Plan period [1] Group 3 - The head of the National Healthcare Security Administration, Zhang Ke, indicated plans to accelerate the construction of a healthcare imaging cloud based on medical insurance data, aiming for nationwide interoperability and recognition of medical insurance imaging by 2027 [4]

Core Insights - The "2025 Innovative Drug High-Quality Development Conference" was held in Guangzhou, announcing the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the first edition of the Commercial Health Insurance Innovative Drug Catalog [1] Group 1: Drug Catalogs - The first edition of the Commercial Health Insurance Innovative Drug Catalog includes 19 drugs, featuring all five CAR-T tumor therapies priced at over one million [1] - High-profile drugs for Alzheimer's disease treatment and rare diseases have also been included in the catalog, reflecting significant public interest [1] Group 2: Industry Perspectives - Fosun Kerry's Chairman Zhang Wenjie emphasized that the quality of innovative drugs is not only determined by the drugs themselves but also by patient accessibility [1] - The negotiation mechanism for commercial insurance is highlighted as a crucial milestone for the accessibility of innovative drugs in China [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 CANbridge Pharmaceuticals Inc. 北海康成製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1228） 於2025年12月4日舉行的股東特別大會的投票表決結果 董事會謹此宣佈，股東特別大會通告所載的所有決議案於2025年12月4日（星期四）舉行的股東特 別大會上獲股東以投票表決方式正式通過。 股東特別大會（「股東特別大會」） | | 普通決議案 | 票數（百分比） | | | --- | --- | --- | --- | | | | 贊成 反對 | | | 1. | 授予本公司董事（「董事」）新一般授權，以配發及發行不超過 | 143,690,478 | 0 | | | 於股東特別大會上通過相關決議案當日本公司已發行股本 | (100%) | (0%) | | | 20%的本公司股份（「股份」）（不包括任何以庫存形式持有的 | | | | | 股份）。 | | | ...

截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北海康成製藥有限公司（於開曼群島註冊成立之有限公司） FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01228 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 510,826,484 | | 0 | | 510,826,484 | | 增加 / 減少 (-) | | | | | | | | | | 本月底結存 | | | | 510,826,484 | | ...

CANbridge Pharmaceuticals Inc. 北海康成製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1228） 於2025年12月4日（星期四）待舉行的股東特別大會適用的代表委任表格 本人╱吾等 （附註1） 茲委任大會主席或 （附註3） 電郵地址為 （電郵地址） 為本人╱吾等之受委代表，代表本人╱吾等出席本公司謹訂於2025年12月4日（星期四）上午九時正透過電子方式虛擬舉行股東特別大會（或 其任何續會）而毋須親自出席（「股東特別大會」），以考慮及酌情通過下列於召開股東特別大會通告所載之決議案，並於大會（或其任何續會） 按下述指示代表本人╱吾等以本人╱吾等之名義就上述決議案投票，若無任何指示，則本人╱吾等之受委代表可自行酌情投票。 | | 普通決議案 | （附註4） 贊成 | （附註4） 反對 | | --- | --- | --- | --- | | 1. | 授予本公司董事（「董事」）新一般授權，以配發及發行不超過於股東特別大會上通過相關決議 | | | | | 案當日本公司已發行股本20%的本公司股份（「股份」）（不包括任何以庫存形式持有的股份）。 | | | | 2. | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 「供股」指於董事指定期間內向於指定記錄日期名列本公司股東名冊的股份或任何類別股份持有 人，按彼等當日持有股份的比例提呈發售股份（惟董事有權就零碎配額或因顧及到適用於本公司 於任何地區的法律限制或責任或任何認可監管機構或任何證券交易所的規定，作出彼等認為必 要或適宜的例外情況或其他安排）。」 2. 「動議待本股東特別大會通告（「通告」）所載第1項決議案獲正式通過後，擴大根據本通告所載第 1項決議案授予董事配發、發行及買賣額外股份（包括任何出售或轉讓庫存股），並作出或授予可 能需行使該等權力的要約、協議及購股權的無條件一般授權，方法為加入相當於本公司根據於 2025年股東週年大會上通過的購回授權所購回股份總數的數額，惟該數額不得超過於2025年股 東週年大會當日已發行股份總數（不包括任何庫存股）的10%。」 承董事會命 北海康成製藥有限公司 董事長 CANbridge Pharmaceuticals Inc ...

此乃要件 請即處理 閣下對本通函任何方面或應採取的行動如有任何疑問，應諮詢 閣下的股票經紀或其他註冊證 券商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓名下全部北海康成製藥有限公司股份，請勿理會本通函及代表委任表格。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性 或完整性亦不發表聲明，並明確表示概不就因本通函全部或任何部分內容而產生或因倚賴該等 內容而引致的任何損失承擔任何責任。 CANbridge Pharmaceuticals Inc. 北海康成製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1228） 建議更新一般授權 及 股東特別大會通告 獨立董事委員會及獨立股東之獨立財務顧問 北海康成製藥有限公司謹訂於2025年12月4日（星期四）上午九時正透過電子方式虛擬舉行股東特別大會而 毋須親自出席，會上將考慮（其中包括）上述建議，召開大會通告載於本通函第N-1頁至第N-4頁。 董事會函件載於本通函第4至13頁。獨立財務顧問函件載於本通函第15至30頁。 股東特別大會適用之代表委任表格亦於本公司網站(www.canbridgepharma. ...